Cabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. Cabergoline possesses potent agonist activity on dopamine D2 receptors.
For the treatment of hyperprolactinemic disorders, either idiopathic or due to prolactinoma (prolactin-secreting adenomas). May also be used to manage symptoms of Parkinsonian Syndrome as monotherapy during initial symptomatic management or as an adjunct to levodopa therapy during advanced stages of disease.
Endocrinology and Female Infertility Department, Reproductive Medicine Research Center, Royan institute, ACECR, Tehran, Iran, Islamic Republic of
Seth GSMC & KEM hospital, Mumbai, Maharashtra, India
Anapharm, Inc., Sainte-Foy, Quebec, Canada
Anapharm, Inc., Sainte-Foy, Quebec, Canada
Pfizer Investigational Site, Zürich, Switzerland
Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, via S. Pansini 5 Naples, Italy
Pfizer Investigational Site, Sevilla, Spain
Department of Nuclear Medicine at the Technical University of Dresden, Dresden, Saxony, Germany
Department of Neurology at the Technical University of Dresden, Dresden, Saxony, Germany
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.